Health Insurance Innovations Leads Top Upgrade List
For today's edition of our upgrade list, we used our website's advanced screening functions to search for UPGRADES to BUY or STRONG BUY with complete forecast and valuation data. They are presented by one-month forecast return. Health Insurance Innovations, Inc. (HIIQ) is our top-rated upgrade this week and it is a STRONG BUY. Our other picks are also STRONG BUY stocks with the exception of NOAH and EPR--which are BUY-rated.
Ticker |
Company Name |
Market Price |
Valuation |
Last 12-M Return |
1-M Forecast Return |
1-Yr Forecast Return |
P/E Ratio |
Sector Name |
HEALTH INS INN |
16.8 |
12.56% |
182.35% |
1.19% |
14.28% |
14.08 |
Finance |
|
ULTRA CLEAN HLD |
13.34 |
12.25% |
150.28% |
1.13% |
13.58% |
15.05 |
Computer and Technology |
|
DISCOVER FIN SV |
71.4 |
8.31% |
46.43% |
1.09% |
13.14% |
12.25 |
Finance |
|
NOAH HLDGS LTD |
27.85 |
-6.21% |
17.16% |
0.60% |
7.17% |
15.59 |
Finance |
|
EPR PROPERTIES |
75.55 |
7.29% |
21.89% |
0.58% |
6.96% |
15.62 |
Finance |
Health Insurance Innovations, Inc. operates as a developer and administrator of web-based individual health insurance plans and ancillary products. Its product portfolio consists of short-term medical plans, accident, sickness & hospital medical plans, ancillary insurance, life insurance, lifestyle and discount services. Health Insurance Innovations, Inc. is based in Tampa, Florida.
The company reported Q4 2016 a loss of $0.04/share last week with earnings--adjusted--of $0.35/share. Revenue was $51.4 million for the reported quarter. Yearly figures included a profit of $4.5 million/share on revenue of $184.5 million. The companies shares have traded is a narrow range since the start of 2017.
Analysts coverage is a mixed bag, with some rating it a BUY and others a HOLD. We have a STRONG BUY on the firm with a target price of $19.20 for the year. This is in line with an average target price of $20 from other analysts.
Of course, almost everything health-care related is up-in-the-air these days as the new Trump administration and their GOP allies in the US Congress are unable/unwilling to deal with ACA/"Obamacare" reforms now that they hold complete power in DC. Their long-term efforts to remove the expanded health-care coverage for millions of Americans have faltered now that the proverbial rubber has met the proverbial road.
It remains to be seen what, if any tweaks will be made to the US health-care system. Trump himself has claimed that "nobody knew health care could be so complicated"--and he was met with widespread derision.
However, "complicated" is a good descriptor. Investors should remain cautious with health care stocks due to possible changes from Washington. But, we are convinced that with each passing day an outright repeal of the ACA seems far less likely. That means that innovators in the field may be well-positioned to profit from more business-friendly reforms from allies in Washington
Below is today's data on Health Insurance Innovations, Inc.:
VALUENGINE RECOMMENDATION: ValuEngine updated its recommendation from BUY to STRONG BUY for Avis Health Insurance Innovations on 2017-02-24. Based on the information we have gathered and our resulting research, we feel that Health Insurance Innovations has the probability to, OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE P/E Ratio and Price Sales Ratio.
ValuEngine Forecast |
||
Target |
Expected |
|
---|---|---|
1-Month |
17.00 | 1.19% |
3-Month |
17.11 | 1.82% |
6-Month |
17.66 | 5.09% |
1-Year |
19.20 | 14.28% |
2-Year |
17.57 | 4.55% |
3-Year |
18.71 | 11.38% |
Valuation & Rankings |
|||
Valuation |
12.56% overvalued |
Valuation Rank(?) |
46 |
1-M Forecast Return |
1.19% |
1-M Forecast Return Rank |
99 |
12-M Return |
182.35% |
Momentum Rank(?) |
97 |
Sharpe Ratio |
0.12 |
Sharpe Ratio Rank(?) |
59 |
5-Y Avg Annual Return |
9.07% |
5-Y Avg Annual Rtn Rank |
71 |
Volatility |
75.96% |
Volatility Rank(?) |
21 |
Expected EPS Growth |
6.93% |
EPS Growth Rank(?) |
34 |
Market Cap (billions) |
0.25 |
Size Rank |
44 |
Trailing P/E Ratio |
14.08 |
Trailing P/E Rank(?) |
82 |
Forward P/E Ratio |
13.17 |
Forward P/E Ratio Rank |
71 |
PEG Ratio |
2.03 |
PEG Ratio Rank |
24 |
Price/Sales |
1.48 |
Price/Sales Rank(?) |
58 |
Market/Book |
8.81 |
Market/Book Rank(?) |
16 |
Beta |
0.28 |
Beta Rank |
72 |
Alpha |
1.07 |
Alpha Rank |
98 |
Disclaimer: ValuEngine.com is an independent research ...
more